Is Hyperfine, Inc. overvalued or undervalued?

As of 11 May 2022, the valuation grade for Hyperfine, Inc. has moved from does not qualify to risky, indicating a shift in its perceived investment quality. The company is currently considered overvalued, given its negative performance metrics and ratios. The P/E ratio is not applicable due to losses, while the Price to Book Value stands at 1.44. Additionally, the EV to Sales ratio is 2.45, which is concerning for a company with such poor profitability indicators.
In comparison to its peers, Hyperfine, Inc. shows a significantly worse EV to EBITDA ratio of -0.68, while Semler Scientific, Inc. has a much healthier EV to EBITDA of 23.87. Jin Medical International Ltd. also presents a stark contrast with an EV to EBITDA of -14.24. Hyperfine's return performance has lagged behind the S&P 500, with a year-to-date decline of 21.17% compared to the index's 2.44% gain, reinforcing the notion that the stock is currently overvalued.